Quest Diagnostics buys cancer test
This article was originally published in The Gray Sheet
Executive Summary
Firm gains InSure fecal immunochemical colorectal cancer screening test, as well as the InSure II version of the test, cleared by FDA in May for use in doctors' offices, via its $45 mil. purchase of privately held Australian company Enterix. The deal, announced Sept. 7, follows Quest's acquisition of HerpeSelect herpes virus test manufacturer Focus Diagnostics for $185 mil. in July. For the second quarter, Quest reported revenue of $1.6 bil., up 15% from the prior-year period...
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.